Neelim Healthcare Consulting
Neelim

Neurology Prometric exam questions

Exam-length papers covering every published domain for Neurology.

Tell us which regulator you are sitting and we send the bank prepared for that authority's exam.

For DHA · MOHAP · SHA · SCFHS · QCHP · NHRADHA NRO5011Pass mark DHA 65% · SCFHS 65% · QCHP 65%From 3 papers · ~175 Qs each
AED 319one-time
About a third of one exam fee
Request this question bank

Tell us your authority and we send the bank for that exam, usually the same day.

Or sit 25 questions free first →

What is riding on this exam

~AED 1,030
DHA exam fee, per attempt
Paid again on every re-sit. Other regulators' fees are in the table below.
3
UAE attempts - in total
Shared across DHA, DOH, MOHAP and SHA, not three each. Saudi, Qatar, Oman and Kuwait rules are in the FAQ.
65%
Pass mark, by regulator
DHA 65%, SCFHS 65%, QCHP 65%. Other regulators in the table below.

One failed attempt costs you the fee again, plus months of delay on your licence, your visa and your start date. This bank costs about a third of one exam fee.

Every regulator: format, pass marks and fees for all GCC licensing exams, each from the regulator's own documents.

The Neurology exam at a glance

DHA (UAE) publishes a Neurology exam of 150 MCQs in 3 hours with a 65% pass mark; SCFHS (Saudi Arabia) publishes a Neurology exam of 200 MCQs in 240 minutes with a 65% pass mark; QCHP (Qatar) publishes a Neurology exam of 150 MCQs in 3 hours with a 65% pass mark. MOHAP, SHA, NHRA do not publish Neurology-specific figures; their regulator-wide format and pass-mark rules are in the full table. DOH licenses the title without a published written exam (credential review, interview or an unpublished assessment). OMSB, Kuwait MOH publish no exam for this title.

DHA · UAE
Specialist Neurology (NRO5011)
150 MCQs in 3 hours · pass mark 65% · USD 280 (about AED 1,030) · checked September 2026
SCFHS · Saudi Arabia
Saudi Classification Examination - Neurology
200 MCQs in 240 minutes · pass mark 65% · checked October 2026
QCHP · Qatar
Specialist Neurology
150 MCQs in 3 hours · pass mark 65% · checked September 2026

From each regulator's own exam documents; the DHA row is from the DHA CBT Guideline, Sep 2026. Every other regulator is in the full GCC table.

Try two questions from this bank

Original questions from the bank - pick an answer to see the rationale and reference.

Q1Patient Safety and Quality in Neurological Care

A stroke team audits door-to-needle times, finds a median of 78 minutes, introduces pre-notification by ambulance and direct-to-CT transfer, and presents the improvement plan at a departmental meeting. Which step is required to complete the audit cycle?

Choose an answer to see the rationale.

Q2Neuro-Immunological and Demyelinating Disorders

A 29-year-old woman with relapsing-remitting multiple sclerosis asks how pregnancy will affect her disease. Which statement should form the basis of your counselling?

Choose an answer to see the rationale.

Not sure where you stand? Sit 25 of these questions free, timed at real exam pace, and see which domains you are weakest in.

Take the free mock exam →

Liked those? The full bank has 520 questions at this standard - every one with a rationale and a reference.

Get the full bank - AED 319

What's inside

  • ✓3 to 6 full-length papers (~175 Q each)
  • ✓No question repeated between papers
  • ✓Four options, one unambiguous best answer
  • ✓A full rationale on every question
  • ✓A real guideline or textbook reference
  • ✓Every sub-topic in the published blueprint
  • ✓Researched by Neelim's exam research team
  • ✓Prepared for your authority's exam, not a generic set

The Neurology exam in every GCC country

Neurology licensing exam in every GCC country
RegulatorExamFormatPass markFee per attempt
Specialist Neurology (NRO5011)
150 MCQs in 3 hours65%USD 280 (about AED 1,030)
SCFHS
Kingdom of Saudi Arabia
Practise →
Saudi Classification Examination - Neurology
200 MCQs in 240 minutes65%Not published
QCHP
State of Qatar
Practise →
Specialist Neurology
150 MCQs in 3 hours65%Not published
DOH
Abu Dhabi, Al Ain and Al Dhafra
Practise →
No written exam published
Oral assessment / interview, confirmed with DOH (Oct 2026); no written exam
Panel / reviewNot publishedNot published
MOHAP
Northern Emirates - Ajman, Umm Al Quwain, Ras Al Khaimah and Fujairah
Practise →
MOHAP licensing exam
Regulator-wide format
Computer-basedNot publishedNot published
SHA
Emirate of Sharjah
Practise →
SHA licensing exam
Regulator-wide format
Set at assessmentNot publishedNot published
NHRA
Kingdom of Bahrain
Practise →
NHRA licensing exam
Regulator-wide format
Prometric CBTNot publishedNot published
OMSB
Sultanate of Oman
Practise →
No exam published for this title
No OMSB exam published for this title; check with OMSB
Not publishedNot publishedNot published
Kuwait MOH
State of Kuwait
Practise →
No exam published for this title
Kuwait MOH publishes no exam for this title; check with the MOH
Not publishedNot publishedNot published

Highlighted rows publish figures for this exact Neurology exam; the others show the regulator's general rules.

From each regulator's own exam pages; anything a regulator does not publish says so. Assessment mode also depends on your licence title, so confirm your route on your eligibility notice.

Try 15 free Neurology questions with answersDifferent from the samples on this page - each with a full explanationStart →

What the Neurology exam covers

The published blueprint for this exam breaks into 13 domains and 260 testable sub-topics. Our bank covers every one of them - here is the full map, so you can see exactly what you are expected to know.

Cerebrovascular Disorders15% (official - DHA/SCFHS blueprint)20 topics
  • Cerebrovascular anatomy: circle of Willis, perforator territories, watershed zones and vascular-territory syndromes
  • Acute ischaemic stroke: NIHSS, ASPECTS scoring, time windows and code-stroke pathways
  • IV thrombolysis with alteplase/tenecteplase: indications, absolute and relative contraindications, dosing, door-to-needle targets
  • Mechanical thrombectomy: large-vessel occlusion selection, extended window imaging (DAWN/DEFUSE-3 criteria), perfusion mismatch
  • Post-thrombolysis complications: symptomatic haemorrhagic transformation, angioedema, blood-pressure protocols
  • TIA assessment, ABCD2 risk stratification, urgent secondary prevention and dual antiplatelet therapy (CHANCE/POINT)
  • +14 more in the bank
Epilepsy and Paroxysmal Disorders15% (official - DHA/SCFHS blueprint)20 topics
  • ILAE 2017 classification of seizure types and epilepsies; definition of epilepsy and of resolved epilepsy
  • First unprovoked seizure: investigation, recurrence risk and when to start an antiseizure medication
  • Focal epilepsies: temporal lobe (mesial temporal sclerosis), frontal, parietal and occipital semiology
  • Idiopathic generalised epilepsies: juvenile myoclonic epilepsy, childhood/juvenile absence, GTCS on awakening
  • Developmental and epileptic encephalopathies: West, Lennox-Gastaut, Dravet, Ohtahara syndromes
  • Self-limited epilepsy with centrotemporal spikes and other benign childhood epilepsies
  • +14 more in the bank
Cephalgia and Headache Disorders15% (official - DHA/SCFHS blueprint)20 topics
  • ICHD-3 classification and the primary/secondary headache framework
  • Red flags for secondary headache (SNNOOP10) and appropriate neuroimaging thresholds
  • Migraine without aura, with aura, and diagnostic criteria; migraine phases (premonitory, aura, headache, postdrome)
  • Migraine with brainstem aura, hemiplegic migraine (FHM1-3) and retinal migraine
  • Acute migraine treatment: NSAIDs, triptans and contraindications, gepants, ditans, antiemetics; parenteral rescue protocols
  • Migraine prophylaxis: beta-blockers, topiramate, valproate, amitriptyline, candesartan, flunarizine, onabotulinumtoxinA for chronic migraine
  • +14 more in the bank
Neuromuscular Disorders7% (official - DHA/SCFHS blueprint)20 topics
  • Localising the lesion: anterior horn cell vs root vs plexus vs nerve vs neuromuscular junction vs muscle
  • Guillain-Barre syndrome and variants (AIDP, AMAN, AMSAN, Miller Fisher): albuminocytological dissociation, IVIG vs plasma exchange, respiratory monitoring with FVC/NIF
  • CIDP and its variants: diagnostic criteria, first-line immunotherapy, distinction from MMN with conduction block and from paraproteinaemic neuropathy
  • Diabetic neuropathies: distal symmetric polyneuropathy, autonomic neuropathy, radiculoplexus neuropathy (diabetic amyotrophy), mononeuropathies
  • Other acquired polyneuropathies: B12/copper deficiency, alcohol, uraemic, hepatic, thyroid, HIV, leprosy, vasculitic (mononeuritis multiplex)
  • Toxic and drug-induced neuropathies: chemotherapy (platinum, taxanes, vincristine), amiodarone, isoniazid, heavy metals
  • +14 more in the bank
Neuro-Immunological and Demyelinating Disorders7% (official - DHA/SCFHS blueprint)20 topics
  • Multiple sclerosis: 2017 McDonald criteria, dissemination in space and time, CSF oligoclonal bands and kappa free light chains
  • Clinically isolated syndrome, radiologically isolated syndrome and the risk of conversion
  • MS phenotypes: relapsing-remitting, secondary progressive, primary progressive; disability measurement with EDSS
  • MS MRI: characteristic lesion locations (periventricular, juxtacortical, infratentorial, spinal cord), Dawson fingers, central vein sign, black holes
  • Acute relapse management: high-dose corticosteroids, plasma exchange for steroid-refractory relapse, pseudo-relapse and Uhthoff phenomenon
  • Disease-modifying therapies: interferons, glatiramer, teriflunomide, dimethyl fumarate, S1P modulators, natalizumab, anti-CD20, cladribine, alemtuzumab
  • +14 more in the bank
Neuro-Infectious Disorders7% (official - DHA/SCFHS blueprint)20 topics
  • Acute bacterial meningitis: empirical antibiotics by age and risk group, adjunctive dexamethasone, timing of CT before LP
  • CSF interpretation: cell count, differential, protein, glucose ratio, lactate, xanthochromia, PCR and multiplex panels
  • Meningococcal disease, pneumococcal meningitis, Listeria, and post-neurosurgical/shunt-related meningitis
  • Viral (aseptic) meningitis: enterovirus, HSV-2, VZV, mumps, HIV seroconversion
  • HSV-1 encephalitis: temporal lobe involvement, EEG PLEDs, urgent aciclovir, post-HSV NMDAR encephalitis
  • Arboviral and endemic encephalitides: West Nile, Japanese encephalitis, dengue, rabies; relevance in Gulf and returning-traveller contexts
  • +14 more in the bank
Movement Disorders7% (official - DHA/SCFHS blueprint)20 topics
  • Phenomenology: distinguishing tremor, chorea, dystonia, myoclonus, tics, athetosis, ballism and ataxia
  • Parkinson disease: MDS clinical diagnostic criteria, supportive and red-flag features, prodromal markers
  • Levodopa therapy, motor fluctuations, wearing-off, on-off phenomena and dyskinesias; delayed-on and dose failure
  • Dopamine agonists and impulse control disorders; MAO-B inhibitors, COMT inhibitors, amantadine, apomorphine, levodopa-carbidopa intestinal gel
  • Deep brain stimulation: STN vs GPi target selection, candidate criteria, contraindications and complications
  • Non-motor features of Parkinson disease: REM sleep behaviour disorder, constipation, hyposmia, orthostatic hypotension, psychosis (pimavanserin/quetiapine/clozapine), depression, dementia
  • +14 more in the bank
Cognitive Disorders7% (official - DHA/SCFHS blueprint)20 topics
  • Cognitive domains and bedside assessment: MMSE, MoCA, ACE-III, clock drawing; culturally and linguistically appropriate testing in the Gulf
  • Delirium vs dementia vs depression: diagnostic distinction, precipitants, prevention bundles and management
  • Mild cognitive impairment: subtypes, biomarkers and conversion risk
  • Alzheimer disease: NIA-AA framework, amyloid/tau/neurodegeneration biomarkers, CSF Abeta42/tau, amyloid PET, plasma p-tau217
  • Alzheimer treatment: cholinesterase inhibitors, memantine, anti-amyloid monoclonal antibodies (lecanemab, donanemab) and ARIA monitoring
  • Dementia with Lewy bodies: fluctuating cognition, visual hallucinations, parkinsonism, REM sleep behaviour disorder, neuroleptic sensitivity, DaTscan/MIBG
  • +14 more in the bank
Clinical Neurophysiology, Neuroanatomical Localization and Neuroimaging5% (official - DHA/SCFHS blueprint; localization/imaging content is examined throughout, per the Brazis 'Localization in Clinical Neurology' reference)20 topics
  • Principles of localization: cortex vs subcortex vs brainstem vs cord vs root vs plexus vs nerve vs junction vs muscle
  • Brainstem syndromes: Wallenberg, Weber, Millard-Gubler, Benedikt, medial medullary; crossed findings
  • Spinal cord syndromes: complete transection, Brown-Sequard, central cord, anterior cord, posterior column, conus vs cauda equina
  • Cranial nerve anatomy and lesions I-XII, including cavernous sinus, orbital apex and jugular foramen syndromes
  • EEG basics: montages, normal awake and sleep rhythms, alpha/beta/theta/delta, normal variants that mimic epileptiform activity
  • Interictal epileptiform discharges, focal vs generalised patterns, 3-Hz spike-and-wave, hypsarrhythmia, slow spike-and-wave
  • +14 more in the bank
Neurology of Systemic Diseases (including Nutritional, Metabolic and Toxic)5% (official - DHA/SCFHS blueprint; footnoted as including nutrition, metabolic, etc.)20 topics
  • Hepatic encephalopathy: grading, precipitants, ammonia, lactulose/rifaximin; acquired hepatocerebral degeneration
  • Uraemic encephalopathy, dialysis disequilibrium syndrome and uraemic neuropathy
  • Electrolyte disturbances: hyponatraemia and osmotic demyelination syndrome, hypernatraemia, calcium and magnesium disorders
  • Endocrine neurology: thyroid (Hashimoto encephalopathy, thyrotoxic periodic paralysis, myopathy), parathyroid, adrenal, pituitary disease and apoplexy
  • Diabetes: hypoglycaemic brain injury, hyperosmolar states, diabetic ketoacidosis with cerebral oedema, neuropathy and stroke risk
  • Nutritional deficiencies: thiamine (Wernicke-Korsakoff, dry beriberi), B12 and subacute combined degeneration, folate, niacin (pellagra), vitamin E, pyridoxine excess and deficiency, copper deficiency after bariatric surgery
  • +14 more in the bank
Neuro-oncology, Neuro-ophthalmology, Neuro-otology and Sleep Neurology~8% (est.; not a separate section in the official DHA/SCFHS blueprint - this content is assessed within the Cognitive, Movement, Systemic Diseases and Clinical Neurophysiology sections, but is commonly examined and must not be omitted)20 topics
  • Primary brain tumours: WHO CNS5 classification, glioma IDH/1p19q status, glioblastoma, meningioma, CNS lymphoma
  • Brain metastases: primary sources, imaging pattern, surgery vs stereotactic radiosurgery vs whole-brain radiotherapy
  • Raised intracranial pressure and cerebral oedema: dexamethasone, mannitol/hypertonic saline, herniation syndromes
  • Tumour-related epilepsy, peri-operative seizure prophylaxis and antiseizure drug interactions with chemotherapy
  • Pituitary tumours, craniopharyngioma, acromegaly and visual field defects; spinal cord tumours and neoplastic cord compression
  • Radiation necrosis vs tumour progression; pseudoprogression on MRI
  • +14 more in the bank
Patient Safety and Quality in Neurological Care5% (official - DHA/SCFHS blueprint; reference: SCFHS 'Essentials of Patient Safety')20 topics
  • Patient safety terminology: adverse event, near miss, sentinel/never event, active failure vs latent condition
  • Swiss cheese model, human factors and systems thinking applied to neurological error
  • Incident reporting, root cause analysis, failure mode and effects analysis (FMEA) and just culture
  • Medication safety in neurology: look-alike/sound-alike antiseizure drugs, high-alert drugs (anticoagulants, thrombolytics, IV valproate/phenytoin), infusion errors
  • Thrombolysis safety: eligibility double-check, blood pressure limits, dosing errors, post-thrombolysis monitoring protocols
  • Anticoagulation stewardship, bridging, reversal pathways and periprocedural management
  • +14 more in the bank
Professionalism, Ethics and Communication5% (official - DHA/SCFHS blueprint; reference: SCFHS 'Professionalism and Ethics, Handbook for Residents')20 topics
  • Core bioethical principles: autonomy, beneficence, non-maleficence, justice, and their application to neurological cases
  • Informed consent: elements, documentation, consent for lumbar puncture, thrombolysis, EEG telemetry, research participation
  • Capacity and competence assessment in cognitive impairment, aphasia and acute confusional states
  • Surrogate decision-making, next-of-kin hierarchy and best-interest determinations in the UAE/GCC legal context
  • Advance directives, do-not-resuscitate orders and withdrawal or withholding of life-sustaining treatment
  • Brain death determination: ethical, legal and religious dimensions; family communication and organ donation discussions
  • +14 more in the bank

12 worked Neurology practice questions

Original exam-style questions from the bank, spread across the blueprint domains. They are not real or recalled exam questions. Try each one, then open the answer for the rationale and reference. None of them appear in the free mock exam, so reading them will not spoil it.

  1. Question 1 · Cerebrovascular Disorders

    A 42-year-old woman with a history of migraine with aura and two prior lacunar strokes has a strong family history of early stroke and dementia. MRI shows confluent white matter hyperintensities involving the anterior temporal poles and external capsules. Which diagnosis and confirmatory test are most appropriate?

    1. ACADASIL; NOTCH3 gene testing
    2. BFabry disease; alpha-galactosidase A activity in a female patient as the definitive test
    3. CMultiple sclerosis; CSF oligoclonal bands
    4. DMELAS; serum lactate
    Show answer and explanation

    Correct answer: A. CADASIL; NOTCH3 gene testing

    Anterior temporal pole and external capsule white matter hyperintensities in a young adult with migraine with aura, recurrent lacunar strokes and a dominant family history are highly characteristic of CADASIL, confirmed by NOTCH3 mutation analysis (skin biopsy showing granular osmiophilic material is an alternative). Enzyme activity is unreliable in heterozygous females with Fabry disease, MS lesions are periventricular and ovoid with Dawson fingers rather than temporopolar, and MELAS produces stroke-like lesions that cross vascular territories with cortical involvement.

    Reference: Chabriat et al., Lancet Neurology 2009; Bradley's Neurology in Clinical Practice, 8th ed. (2022)

  2. Question 2 · Cephalgia and Headache Disorders

    A 38-year-old woman has 14 attacks per day of severe right orbital pain, each lasting about 15 minutes, accompanied by right lacrimation, conjunctival injection and nasal congestion. MRI of the brain including pituitary views is normal. Which management step is both diagnostic and therapeutic?

    1. AA trial of high-flow oxygen at 12 L/min for 15 minutes
    2. BA supervised trial of indometacin titrated to an adequate dose
    3. CA trial of carbamazepine 200 mg twice daily
    4. DA trial of subcutaneous sumatriptan 6 mg for each attack
    Show answer and explanation

    Correct answer: B. A supervised trial of indometacin titrated to an adequate dose

    Multiple short attacks (2-30 minutes) occurring many times daily with prominent cranial autonomic features is the pattern of paroxysmal hemicrania, which by definition shows an absolute response to adequate doses of indometacin; the indometacin trial therefore confirms the diagnosis and treats the condition (with gastroprotection). Oxygen and subcutaneous sumatriptan abort cluster attacks, which are longer (15-180 minutes) and far less frequent, and carbamazepine is used for trigeminal neuralgia, where autonomic features are absent or minimal.

    Reference: ICHD-3, International Headache Society 2018; Continuum (AAN) Headache issue, 2021

  3. Question 3 · Neuromuscular Disorders

    A 26-year-old woman reports stiffness of the hands and eyelids that is mild on the first contraction and becomes progressively worse with each repeated movement, and is markedly aggravated by cold weather. Her father is similarly affected. Which statement best characterises this disorder?

    1. AIt is myotonia congenita due to CLCN1 mutations, in which myotonia improves with repeated activity (the warm-up phenomenon)
    2. BIt is neuromyotonia due to voltage-gated potassium channel complex antibodies, in which stiffness persists during sleep
    3. CIt is myotonic dystrophy type 1, in which stiffness is accompanied by distal weakness, cataracts and cardiac conduction disease
    4. DIt is paramyotonia congenita due to SCN4A mutations, in which myotonia paradoxically worsens with repeated activity and with cold
    Show answer and explanation

    Correct answer: D. It is paramyotonia congenita due to SCN4A mutations, in which myotonia paradoxically worsens with repeated activity and with cold

    Myotonia that intensifies with repetition (paradoxical myotonia) and is provoked by cold, inherited in an autosomal dominant pattern, defines paramyotonia congenita caused by gain-of-function mutations in the skeletal muscle sodium channel gene SCN4A; mexiletine is the treatment of choice. Chloride channel myotonia congenita shows the opposite warm-up phenomenon; myotonic dystrophy has multisystem features absent here; acquired neuromyotonia is immune-mediated with continuous muscle fibre activity and autonomic features rather than cold-induced paradoxical myotonia.

    Reference: Statland JM and Barohn RJ, Continuum: Lifelong Learning in Neurology (2013), Muscle channelopathies; GeneReviews, Non-dystrophic Myotonia (updated 2021)

  4. Question 4 · Neuro-Infectious Disorders

    A 19-year-old man with untreated sinusitis presents with high fever, severe headache, rapidly declining consciousness, seizures and a dense hemiparesis over 24 hours. MRI shows a crescentic extra-axial collection over the convexity with restricted diffusion, marked dural enhancement and midline shift. What is the most appropriate immediate management?

    1. AIntravenous antibiotics alone, with surgery only if there is no improvement after 72 hours
    2. BMannitol and antiseizure medication alone
    3. CAnticoagulation for presumed septic venous thrombosis before any surgery
    4. DEmergency neurosurgical drainage (craniotomy or burr holes) together with intravenous antibiotics and antiseizure medication
    Show answer and explanation

    Correct answer: D. Emergency neurosurgical drainage (craniotomy or burr holes) together with intravenous antibiotics and antiseizure medication

    Subdural empyema is a neurosurgical emergency: the collection is in a space with no barrier to spread, deterioration is rapid, and delay in drainage is associated with markedly worse outcome, so urgent evacuation plus antibiotics and seizure control is required. Medical therapy alone or osmotherapy alone does not evacuate the pus, and anticoagulation for possible septic venous thrombosis is a secondary consideration that must not delay operative drainage.

    Reference: Bradley's Neurology in Clinical Practice, 8th edition (2022); Brouwer & van de Beek, Epidemiology, diagnosis and treatment of intracranial suppuration (2017)

  5. Question 5 · Cognitive Disorders

    A 28-year-old man of consanguineous parents has progressive cognitive decline and a spastic ataxic gait. He had bilateral cataracts removed at age 9, has chronic diarrhoea since childhood, and has firm nodular swellings over both Achilles tendons. MRI shows dentate nucleus hyperintensity and cerebellar white matter change. Which is the most likely diagnosis?

    1. ANiemann-Pick disease type C
    2. BCerebrotendinous xanthomatosis
    3. CX-linked adrenoleukodystrophy
    4. DWilson disease
    Show answer and explanation

    Correct answer: B. Cerebrotendinous xanthomatosis

    Cerebrotendinous xanthomatosis is an autosomal recessive CYP27A1 defect and the combination of juvenile cataracts, chronic infantile diarrhoea, tendon xanthomas, dementia and spastic ataxia with dentate nucleus signal change is nearly pathognomonic; the diagnosis is confirmed by elevated plasma cholestanol and is treatable with chenodeoxycholic acid, so early recognition matters greatly. Niemann-Pick type C causes vertical supranuclear gaze palsy, splenomegaly and gelastic cataplexy without tendon xanthomas. Adrenoleukodystrophy is X-linked with adrenal insufficiency and posterior parieto-occipital white matter change, and Wilson disease produces Kayser-Fleischer rings and hepatic dysfunction rather than tendon xanthomas or cataracts.

    Reference: Nie S et al., Cerebrotendinous xanthomatosis: a comprehensive review, Orphanet J Rare Dis 2014; Bradley's Neurology in Clinical Practice, 8th edition (2022)

  6. Question 6 · Neurology of Systemic Diseases (including Nutritional, Metabolic and Toxic)

    A 52-year-old woman who had a gastric bypass eight years ago presents with a spastic paraparesis, impaired vibration and joint position sense, a sensory ataxia and a macrocytic anaemia with neutropenia. Serum vitamin B12, methylmalonic acid and homocysteine are all normal. She has been taking a high-dose zinc supplement for her skin. What is the most likely deficiency?

    1. ACopper
    2. BFolate
    3. CVitamin E
    4. DNiacin
    Show answer and explanation

    Correct answer: A. Copper

    Acquired copper deficiency, typical after bariatric surgery or with excess zinc intake (zinc induces enterocyte metallothionein, which sequesters copper), produces a myeloneuropathy clinically indistinguishable from subacute combined degeneration but with normal B12, methylmalonic acid and homocysteine, plus anaemia and neutropenia. Folate deficiency causes macrocytosis with raised homocysteine and rarely a myelopathy. Vitamin E deficiency causes spinocerebellar ataxia with retinopathy but not neutropenia, and niacin deficiency causes pellagra with dermatitis, diarrhoea and dementia.

    Reference: Kumar, Copper deficiency myelopathy (human swayback) (Mayo Clinic Proceedings, 2006); AAN Continuum: Neurologic Complications of Systemic Disease

  7. Question 7 · Professionalism, Ethics and Communication

    The same patient, alone with you the following morning, looks at you directly and asks: 'Doctor, is this a brain cancer, and how long do I have?' Her sons have asked you not to tell her. What should you do?

    1. AReply that you cannot discuss this without her sons present
    2. BSay that the tests are inconclusive and that more time is needed
    3. CTell her the family has asked you not to discuss the results
    4. DAnswer her question honestly and sensitively at the level of detail she is asking for, check her understanding, and afterwards explain to the sons why you were obliged to respond
    Show answer and explanation

    Correct answer: D. Answer her question honestly and sensitively at the level of detail she is asking for, check her understanding, and afterwards explain to the sons why you were obliged to respond

    When a competent patient directly asks for her diagnosis, the duty of veracity and her right to information override a family's request for concealment; deceiving her would be a clear breach of professional integrity. Deflection or an outright lie ('inconclusive') damages trust irreparably once the truth emerges. Telling her only that the family has forbidden disclosure evades her question and sets her against her sons; the correct sequence is to answer her, then talk the family through the reasoning and support them.

    Reference: WMA International Code of Medical Ethics (revised 2022); GMC Good Medical Practice (2024)

  8. Question 8 · Epilepsy and Paroxysmal Disorders

    A 14-year-old boy with Lennox-Gastaut syndrome has multiple daily atonic drop attacks causing repeated facial injuries despite four antiseizure medications and the ketogenic diet. MRI is normal and EEG shows diffuse slow spike-and-wave with no single focus. Which surgical option is most appropriate?

    1. ASelective amygdalohippocampectomy
    2. BFunctional hemispherotomy
    3. CMultiple subpial transections of the motor cortex
    4. DCorpus callosotomy
    Show answer and explanation

    Correct answer: D. Corpus callosotomy

    Corpus callosotomy is an established palliative procedure that interrupts interhemispheric spread and is most effective specifically for atonic drop attacks in generalised epileptic encephalopathies without a resectable focus, markedly reducing injury even though it rarely produces seizure freedom. Amygdalohippocampectomy requires a mesial temporal focus and hemispherotomy requires diffuse unilateral hemispheric pathology, neither of which is present with normal MRI and generalised discharges. Multiple subpial transection is used for epileptogenic tissue within eloquent cortex, not for generalised drop attacks.

    Reference: Cross JH et al., Proposed criteria for referral and evaluation of children for epilepsy surgery, Epilepsia 2006; Bradley's Neurology in Clinical Practice, 8th edition, 2022

  9. Question 9 · Neuro-oncology, Neuro-ophthalmology, Neuro-otology and Sleep Neurology

    A 61-year-old diabetic man has 12 hours of continuous vertigo, vomiting and unsteadiness. He has spontaneous left-beating horizontal nystagmus that does not change direction on gaze, a normal head impulse test bilaterally, and a vertical misalignment on cover testing. What do these HINTS findings indicate?

    1. AA peripheral cause, most likely vestibular neuritis
    2. BBenign paroxysmal positional vertigo of the posterior canal
    3. CA central cause, most likely posterior circulation stroke
    4. DMeniere disease
    Show answer and explanation

    Correct answer: C. A central cause, most likely posterior circulation stroke

    In acute vestibular syndrome a normal (negative) head impulse test, direction-changing nystagmus, or skew deviation on cover testing each point to a central lesion, and HINTS performed by a trained examiner is more sensitive than early MRI for posterior circulation stroke. Vestibular neuritis gives an abnormal head impulse with a corrective saccade, unidirectional nystagmus and no skew. BPPV causes brief positional attacks rather than continuous vertigo, and Meniere disease produces episodic vertigo with fluctuating hearing loss and aural fullness.

    Reference: Kattah JC et al., HINTS to diagnose stroke in the acute vestibular syndrome, Stroke 2009; Barany Society diagnostic criteria

  10. Question 10 · Neuro-Immunological and Demyelinating Disorders

    A 40-year-old woman with biopsy-proven neurosarcoidosis causing a progressive hypothalamic-pituitary syndrome and parenchymal brainstem lesions continues to deteriorate clinically and radiologically despite nine months of high-dose corticosteroids and an adequate trial of methotrexate. Which is the most appropriate next treatment?

    1. AInfliximab
    2. BNatalizumab
    3. CMonthly intravenous immunoglobulin
    4. DPlasma exchange
    Show answer and explanation

    Correct answer: A. Infliximab

    TNF-alpha is central to granuloma formation, and infliximab has the best evidence of any third-line agent for refractory neurosarcoidosis, producing radiological and clinical improvement in a majority of steroid- and antimetabolite-refractory patients; screening for latent tuberculosis and hepatitis B is required first. Natalizumab, IVIG and plasma exchange have no established role in granulomatous CNS disease.

    Reference: Stern BJ et al. JAMA Neurology 2018; Gelfand JM et al. Infliximab for the treatment of CNS sarcoidosis: a multi-institutional series. Neurology 2017

  11. Question 11 · Movement Disorders

    A 58-year-old woman with Parkinson disease reports that her morning dose of levodopa often takes more than 90 minutes to take effect and that the dose taken with her large midday meat-based meal frequently produces no benefit at all. She takes all doses with food and complains of bloating and constipation. Which is the most appropriate initial management?

    1. AIncrease every levodopa dose by 50 per cent
    2. BAdd amantadine
    3. CAdd a dopamine agonist at midday
    4. DGive levodopa 30 to 60 minutes before meals, redistribute dietary protein away from daytime doses, and treat the constipation and delayed gastric emptying
    Show answer and explanation

    Correct answer: D. Give levodopa 30 to 60 minutes before meals, redistribute dietary protein away from daytime doses, and treat the constipation and delayed gastric emptying

    Delayed-on and dose failure in Parkinson disease usually reflect delayed gastric emptying and competition between dietary large neutral amino acids and levodopa for intestinal and blood-brain barrier transport, so timing, protein redistribution and treatment of gastroparesis and constipation are the first interventions. Simply increasing the dose risks peak-dose dyskinesia without correcting absorption; amantadine treats dyskinesia rather than absorption failure; adding an agonist adds adverse effects without addressing the mechanism.

    Reference: Fox SH et al. MDS evidence-based medicine review update on treatments for the motor symptoms of Parkinson's disease. Movement Disorders, 2018; Bradley and Daroff's Neurology in Clinical Practice, 8th edition, 2022

  12. Question 12 · Cognitive Disorders

    The family of a man with dementia and persistent, distressing persecutory delusions ask about the risks of the antipsychotic you have proposed. Which statement is the most accurate counselling point?

    1. AAtypical antipsychotics reduce all-cause mortality in dementia by decreasing agitation-related injury
    2. BThe increased cerebrovascular risk applies to Alzheimer disease but not to vascular or mixed dementia
    3. CAntipsychotics are associated with an increased risk of death and cerebrovascular events in dementia, so they should be used at the lowest effective dose for the shortest time, with a documented indication and regular review for withdrawal
    4. DOnce an antipsychotic is effective it should be continued indefinitely, as withdrawal reliably causes relapse
    Show answer and explanation

    Correct answer: C. Antipsychotics are associated with an increased risk of death and cerebrovascular events in dementia, so they should be used at the lowest effective dose for the shortest time, with a documented indication and regular review for withdrawal

    Meta-analyses and regulatory reviews demonstrate roughly a 1.5 to 1.7-fold increase in mortality and an increased incidence of stroke with both typical and atypical antipsychotics in elderly patients with dementia, which underpins the boxed warning and the guidance to prescribe the lowest effective dose for the shortest period with regular review. The risk is not confined to any single dementia subtype and is at least as high in vascular and mixed disease. Withdrawal trials show that most patients can discontinue without relapse, so indefinite continuation is not justified, although patients with severe psychosis who initially responded strongly need particularly careful, gradual withdrawal.

    Reference: Schneider LS, Dagerman KS, Insel P, Risk of death with atypical antipsychotic drug treatment for dementia, JAMA 2005; NICE NG97 (2018); US FDA boxed warning on antipsychotics in elderly patients with dementia-related psychosis

Neurology reference books and guidelines

Every question in this bank names the textbook or guideline its answer rests on. These are the sources our Neurology questions cite most often - the reading list to revise from alongside the bank.

Textbooks

10
  1. 1

    Bradley's Neurology in Clinical Practice

    8th edition2022
  2. 2

    Brazis, Masdeu and Biller, Localization in Clinical Neurology

    7th edition2021
  3. 3

    DSM-5-TR (American Psychiatric Association)

    2022
  4. 4

    International Classification of Headache Disorders

    3rd edition
  5. 5

    Osborn's Brain

    2nd edition2018
  6. 6

    AHRQ Health Literacy Universal Precautions Toolkit

    3rd edition2024
  7. 7

    Closing the loop, Archives of Internal Medicine

    2003
  8. 8

    Fahn, Jankovic and Hallett, Principles and Practice of Movement Disorders

    3rd edition2021
  9. 9

    MDS evidence-based medicine review update on treatments for the motor symptoms of Parkinson's disease. Movement Disorders

    2018
  10. 10

    Ebersole & Pedley, Current Practice of Clinical Electroencephalography

    4th edition2014

Guidelines and standards

10
  1. 1

    AHA/ASA Guidelines for the Early Management of Patients with Acute Ischemic Stroke

    2019
  2. 2

    NICE clinical guideline, Delirium: prevention, diagnosis and management

    CG1032023
  3. 3

    American Headache Society Position Statement on integrating CGRP-targeting therapies into migraine management, Headache

    2024
  4. 4

    NICE: Spinal metastases and metastatic spinal cord compression

    NG2342023
  5. 5

    AHA Scientific Statement on the Management of Cocaine-Associated Chest Pain and Myocardial Infarction (Circulation)

    2008
  6. 6

    AHA/ASA Guideline for the Management of Spontaneous Intracerebral Haemorrhage

    2022
  7. 7

    American Headache Society Consensus Statement: Integrating New Migraine Treatments into Clinical Practice. Headache

    2021
  8. 8

    AHA/ASA Secondary Prevention Guideline

    2021
  9. 9

    WHO Expert Consultation on Rabies, Third Report and WHO rabies vaccines position paper

    2018
  10. 10

    AHA/ASA Target: Stroke Phase III and the AHA/ASA Acute Ischemic Stroke Guidelines

    2019

Where your regulator publishes a reading list, use the editions it names. Exam questions are not taken from any one book.

Last reviewed September 2026

About these questions: every question is original, researched by Neelim's exam research team, written to the published blueprint, with a rationale and a reference. No recalled or leaked exam content is used. How we write our questions.

Frequently asked questions

Are these real Neurology exam questions?
No. Every item is original, researched by Neelim's exam research team against the exam blueprint published by the health authorities. Real, recalled or leaked exam content breaches the testing bodies' rules and can lead to a permanent exam ban - we do not sell it, and neither should anyone else.
How many questions are in the Neurology bank?
Every bank starts at 3 full-length papers of roughly 175 questions each (the DHA exam itself is 150 questions), and you can add papers up to 6, including a bonus paper of our hardest questions. The papers do not overlap, so every question is new, and together they cover every sub-topic in the published blueprint.
What is the pass mark for the DHA Neurology exam?
65%. DHA publishes the pass score for each exam, and 65% is the figure for Specialist Neurology (NRO5011) in the DHA CBT Guideline, Sep 2026. The result is posted to your Sheryan account as Pass or Fail only - your score is not shared. Elsewhere in the GCC: SCFHS 65%, QCHP 65%.
How many questions are in the DHA Neurology exam, and how long is it?
150 multiple-choice questions in 3 hours, and the time includes registration and the introduction. It is a computer-based test delivered by Prometric at test centres in the UAE and abroad.
How much does the DHA Neurology exam cost?
USD 280 (about AED 1,030) per attempt, paid again for every re-sit. DHA also charges a flat AED 200 credentialing fee through Sheryan.
How many attempts do I get?
In the UAE, three in total across DHA, DOH, MOHAP and SHA, not three each, under clause 1.5.4 of the Unified PQR (April 2025). Clause 1.5.5 allows one further attempt with a different authority, except on the Consultant route. Elsewhere in the GCC: SCFHS up to 4 a year, QCHP 5 per scope, OMSB no set maximum, Kuwait MOH 3, 6 weeks apart.
Which GCC regulators license the Neurology title?
DHA sets a written exam (Specialist Neurology (NRO5011)); SCFHS sets a written exam (Saudi Classification Examination - Neurology); QCHP sets a written exam (Specialist Neurology). DOH licenses the title without a published written exam (credential review, interview or an unpublished assessment). OMSB, Kuwait MOH publish no exam for this title. This bank prepares you for the written exams, and its content is the core knowledge any interview or assessment for the title draws on.
How do I receive it?
As PDF files. Card checkout is being set up, so for now you request it from this page and we send it to you directly, usually the same day.

Still unsure whether you even need this exam?

Your route depends on your profession, your licence title and the authority. We have guided over 1,000 professionals through GCC licensing - tell us your situation and we will confirm exactly what you need to sit.